Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II
申请人:——
公开号:US20030139409A1
公开(公告)日:2003-07-24
A compound which is a benzo[a]phenazine-11-carboxamide derivative of formula (I) wherein each of R
1
to R
4
, which are the same or different, is selected from hydrogen, halogen, hydroxyl, C
1
-C
6
alkoxy which is unsubstituted or substituted, heteroaryloxy, C
1
-C
6
alkyl which is unsubstituted or substituted, nitro, cyano, azido, amidoxime, CO
2
R
10
, CON(R
12
)
2
, OCON(R
12
), SR
10
, SOR
11
, SO
2
(R
11
), SO
2
N(R
12
)
2
, N(R
12
)
2
, NR
10
SO
2
R
11
, N(SO
2
R
11
)
2
NR
10
(CH
2
)
n
CN, NR
10
COR
11
, OCOR
11
or COR
10
; each of R
5
to R
7
, which are the same or different, is selected from hydrogen, halogen, hydroxy, C
1
-C
6
alkoxy, C
1
-C
6
alkyl, SR
10
and N(R
12
)
2
; Q is C
1
-C
6
alkylene which is unsubstituted or substituted by (i) C
1
-C
6
alkyl which is unsubstituted or substituted, (ii) hydroxy, provided that the hydroxy group is not, to either of the N atoms adjacent to Q in formula (I), (iii) CO
2
R
10
, or (iv) CON(R
12
); R
1
and R
9
, which are the same or different, are each hydrogen or C
1
-C
6
alkyl, or R
8
and R
9
together with the nitrogen atom to which they are attached form a saturated 5- or 6-membered N-containing heterocyclic ring which may include one additional heteroatom selected from O, N and S, or one of R
8
and R
9
is an alkylene chain optionally interrupted by O, N or S, which is attached to a carbon atom on the alkylene chain represented by Q to complete a saturated 5- or 6-membered N-containing heterocyclic ring as defined above; or a pharmaceutically acceptable salt thereof; with the proviso that at least one R
1
to R
4
is other than hydrogen. These compounds are inhibitors of topoisomerase I and/or topoisomerase II and can be used to treat tumours, including tumours which express MDR.
一种化合物,是一种公式(I)的苯并[a]菲啉-11-甲酰胺衍生物,其中R1至R4中的每一个,它们相同或不同,被选择为氢、卤素、羟基、未取代或取代的C1-C6烷氧基、杂环氧基、未取代或取代的C1-C6烷基、硝基、氰基、叠氮基、酰肼基、CO2R10、CON(R12)2、OCON(R12)、SR10、SOR11、SO2(R11)、SO2N(R12)2、N(R12)2、NR10SO2R11、N(SO2R11)2NR10(CH2)nCN、NR10COR11、OCOR11或COR10;R5至R7中的每一个,它们相同或不同,被选择为氢、卤素、羟基、C1-C6烷氧基、C1-C6烷基、SR10和N(R12)2;Q是未取代或取代的C1-C6烷基,其被(i)未取代或取代的C1-C6烷基,(ii)羟基、前提是羟基不是在公式(I)中与Q相邻的任一N原子,(iii)CO2R10,或(iv)CON(R12)所取代;R1和R9,它们相同或不同,分别是氢或C1-C6烷基,或R8和R9连同它们连接到的氮原子形成饱和的5-或6-成员N-含杂环戊或六元环,可能包括一个额外的由O、N和S中选择的杂原子,或R8和R9中的一个是由O、N或S随机中断的烷基链,它连接到由Q表示的烷基链上的碳原子,以完成上述定义的饱和的5-或6-成员N-含杂环戊或六元环;或其药学上可接受的盐;但至少一个R1到R4不是氢。这些化合物是拓扑异构酶I和/或拓扑异构酶II的抑制剂,可用于治疗肿瘤,包括表达MDR的肿瘤。